skip to content

Clinical Trials

MainTitle

Prevention of HIV in "Île-de-France" (ANRS-PREVENIR)

This study is currently recruiting participants. (see Contacts and Locations)

Verified May 2017 by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Sponsor
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)


Information provided by (Responsible Party)
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier
NCT03113123

First received: April 10, 2017
Last updated: May 12, 2017
Last Verified: May 2017
History of Changes
Purpose

Purpose

Interventional HIV prevention strategy based on pre-exposure prophylaxis (PrEP) with Truvada® for people in the Île-de-France area (or Paris region) who don't have HIV but who are at high risk of becoming infected with HIV (men who have sex with men (MSM), transgender men and women, heterosexual men and women, sex workers, migrants) in combination with overall prevention services (communautary-based or educational counselling; addiction, social and psychological care; condoms and lubricating gel; clean injection equipment; sexually transmitted diseases (STD) screening and treatment; hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) vaccinations and post-exposure treatment of HIV infection as soon as possible after diagnosis using an antiretroviral combination recommended by the French Guidelines on HIV treatment).

The individual benefit being already demonstrated in clinical trials, the aim is to demonstrate the public health impact of the interventional HIV prevention strategy by reducing the risk of getting HIV-1 infection of at least 15% of new diagnosis of HIV infections among MSM/transgender in the Ile-de-France area after a 3-year period.

Condition Intervention
HIV Infections

Drug : PrEP with Truvada®

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prevention of HIV in "Île-de-France"

Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

Primary Outcome Measures

  • Reduction of new HIV diagnosis [ Time Frame: three years ]
    Number of new HIV infections
Secondary Outcome Measures:
  • Number of recent infections [ Time Frame: three years ]
    Impact of the study on the total number and on recent HIV infections in Île-de- France, and in each key subgroup
  • Prevalence of HIV-infection at the screening visit (undiagnosed epidemic) [ Time Frame: two years ]
    Number of HIV-infected persons at screening visit
  • Incidence of HIV infection [ Time Frame: three years ]
    Incidence of HIV infection in Paris and in the Île-de-France area according to back-calculation approach, and by key subgroups (MSM, transgenders, migrants, etc.)
  • Retention in the study [ Time Frame: two years ]
    Retention in the study, reasons for consent withdrawal
  • Counselling [ Time Frame: three years ]
    Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP
  • Type of counselling [ Time Frame: three years ]
    Impact of counselling according to the type of counselling provided: communautary-based or educational
  • Post-exposure prophylaxis [ Time Frame: three years ]
    Evaluate the participants' need for post-exposure prophylaxis during the course of the study
  • Adherence to PrEP [ Time Frame: three years ]
    Evaluation of adherence by self-administered online questionnaires on last sexual intercourse Questionnaire on the use of PrEP during the last month prioir to study visit Dried blood spots to assess TVF-DP and/or FTC-TP in red cells
  • PrEP dosing schedule [ Time Frame: three years ]
    Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study
  • Safety and tolerability [ Time Frame: three years ]
    Assessment of PrEP tolerability and safety particularly: incidence of drug-related adverse events, incidence of grade 3-4 adverse events, incidence of adverse events leading to PrEP discontinuation
  • Incident HIV infections [ Time Frame: three years ]
    Comprehensive study of incident HIV infections in those on PrEP Incidence of HIV-infection on PrEP Emergence of drug-associated resistance mutations (in particular FTC and tenofovir- mutations at positions 184, 65, and 70 in reverse transcriptase gene) Adherence to PrEP at the closest visit before HIV seroconversion and at previous visits
  • Participants Behavior [ Time Frame: three years ]
    Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study. Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up Number of partners during the previous 2 months Number of sexual intercourses during the previous 4 weeks Use of condom at last sexual intercourse Incidence of STIs
  • Integration of PrEP in the daily routine of participants [ Time Frame: three years ]
    Factors associated with the integration of PrEP in the daily routine of participants - Qualitative study to explore the motivations, difficulties, behavior and expectations of the participants, their knowledge and communication on their use of PrEP. We will focus on: Change in the use of sexual networks (internet, sex clubs, backrooms, sauna) Feeling of sexual well-being during sexual intercourse (less worried about getting HIV infection) Condom use (withdrawal of condom use)
  • Care Providers Behavior [ Time Frame: three years ]
    Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study
  • Social epidemiology [ Time Frame: three years ]
    Evaluation of social and/or territorial inequalities and disparities through collection of relevant indicators Socio-economic status Social insertion: marital status etc. Origin (according to Ined definition) : french, french born from immigrant parents, immigrants Précar score Socio-economical background (according to IRIS indicator)
  • Cost-effectiveness [ Time Frame: three years ]
    Cost-effectiveness of the comprehensive prevention strategy provided in this study

Estimated Enrollment: 3000
Study Start Date: May 3, 2017
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: April 2020 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Other: PrEP with Truvada®
On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours.
Drug: PrEP with Truvada®
    Associated with:
    • STD screening/treatment for syphilis, gonorrhoea and chlamydiae
    • HIV screening/therapy
    • Questionnaire
    • Addiction, social or psychological follow-up care if needed
    • Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.

    Other Name: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)

    Detailed Description:

    Assuming the PrEP efficacy of 80% and that 85% of included participants being MSM - the objective is to evidence a decrease of at least 15% of new diagnosis of HIV infections among MSM in Ile-de-France area. This objective is in the framework of a commitment of large cities against AIDS with the political support of the City of Paris for the "Paris sans SIDA" program and the commitment of the Île-de-France area.

    Secondary

      Objectives:
      • Prevalence of HIV infection at the screening visit (undiagnosed epidemic)
      • Incidence of HIV infection according to back-calculation approach, and by key subgroups

      Operational Objectives:
    • Evaluate the origin of the recruitment according to the risk groups and the outreach actions
    • Assess linkage to care for PrEP, retention in the study, reasons for consent withdrawal and satisfaction of the participants according to the screening site, the type of PrEP supply, the costs of global care, the key subgroups, the type of counselling, the time from STD testing to initiation of PrEP treatment in study sites
    • Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP by comparing the incidence observed in MSM enrolled in the current study to that evidenced in the ANRS IPERGAY trial, with a method similar to that used in the Partner demonstration project in Kenya and Uganda.
    • Impact of the communautary-based and educational counselling

    Clinical Objectives:
  • Estimation, in individuals seeking for PrEP and thus getting tested for HIV infection, the prevalence of HIV infection in different key subgroups, which is a surrogate marker of the undiagnosed (or "hidden") epidemic
  • Evaluate who will become HIV-infected during the course of the study while on PrEP, the proportion of patients on combined antiretroviral treatment and the proposition of patients with a suppressed HIV viral load 12 months after HIV infection
  • Evaluate the participants' need for post-exposure prophylaxis during the course of the study
  • Adherence to PrEP (questionnaire and dried blood spots)
  • Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study
  • Assessment of PrEP tolerability and safety
  • Comprehensive study of incident HIV infections in those on PrEP (incidence, emergence of drug-associated resistance mutations, adherence to PrEP at the closest visit before HIV seroconversion and at previous visits)

  • Participants Behavior:
  • Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study, and retention in the study.
  • Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up
  • Factors associated with the integration of PrEP in the daily routine of participants:
    • Qualitative study to explore the motivations, difficulties, behavior and expectations of the participants, their knowledge and communication on their use of PrEP
    • Reasons related to the choice of the prevention strategy used in terms of dosing
    schedule (continuous or on demand in MSM) and type of counselling and participation to focus groups.

  • Care Providers Behavior: Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study
    Social epidemiology: Evaluation of social and/or territorial inequalities and disparities
    Cost-effectiveness of the comprehensive prevention strategy

    Eligibility

    Eligibility

    Ages Eligible for Study: 18 Years and older  
    Sexes Eligible for Study: All  
    Accepts Healthy Volunteers: Yes  

    Criteria

    Inclusion Criteria:

    • Age ≥ 18 years
    • Men/transgender men/women who have sex with men, heterosexual men and women, sex workers
    • Negative for HIV-1 and HIV-2 (with a fourth generation enzyme-linked immunosorbent assay (ELISA) assay)
    • Willing the geocoding of the postal address and to be contacted via telephone or email, on a regular basis
    • Willing to comply to visits schedule (every 3 months)
    • Health security program
    • Informed consent form signed
    • High risk of acquiring HIV infection:
      • For MSM and transgenders:
        • Anal sex with at least two different sexual partners and no consistent condom use over the last 6 months
        • And/or history of STD during the last 12 months (syphilis, gonorrhea , chlamydiae, HBV or HCV infection)
        • And/or history of non-occupational post-exposure prophylaxis (PEP) during the last 12 months
        • And/or using psycho-actives drugs during sexual intercourses (cocaine, gammahydroxybutyric acid (GHB), Methylenedioxymethamphetamine (MDMA), mephedrone)
        • And/or having an HIV-infected sexual partner with a detectable plasma viral load (> 50 copies (cp)/milliliter (ml))
      • For heterosexual:
        • Sexual intercourse with 1 partner originating from regions with high prevalence of HIV infection (> 1%) (South America, Sub-Saharan Africa, South-East Asia, Eastern Europe, French Guyana) and no consistent condom use
        • and/or sex workers
        • and/or having a sexual partner who is an intravenous drug users sharing injection material
        • and/or having an HIV-infected sexual partner with a detectable plasma viral load (> 50 cp/ml)


        Exclusion Criteria:
    • Stable and exclusive relationship with an HIV-negative partner, or with an HIV-positive partner on antiretroviral therapy (ART) with a plasma viral load < 50 cp/ml
    • Positive HIV infection
    • Clinical signs of positive HIV infection
    • Consistent condom use during sexual intercourse
    • Expected trip abroad for 3 consecutive months
    • Creatinine clearance lower than 50ml/min
    • History of chronic renal disease, osteoporosis or osteopenia
    • Receiving an investigational drug
    • Receiving or will receive potentially nephrotoxic treatments
    • Gastro-intestinal condition that could limit drug absorption
    • Potentially non compliant participants
    • Breastfeeding
    • Hypersensitivity to TDF/FTC
    • Positive HBs antigen or isolated anti hepatitis B core (HBc) antibodies if not willing to take daily PrEP
    • Severe condition (lymphoma, other cancers, cardio-vascular disease, end-stage renal
    failure, uncontrolled diabetes)

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT03113123

    Contacts

    Contact:   Jean-Michel MOLINA, Pr 0142499066 jean-michel.molina@aphp.fr
    Contact:   Jade GHOSN, MD 0142348836 jade.ghosn@aphp.fr

    Locations

    France
    Hôpital Avicenne Not yet recruiting
    Bobigny, France, 93000
    Contact: Olivier Bouchaud, MD
    Principal Investigator: Olivier Bouchaud, MD
    Hôpital Jean Verdier Not yet recruiting
    Bondy, France, 93143
    Contact: Vincent Jeantils, MD
    Principal Investigator: Vincent Jeantils, MD
    Hôpital Ambroise-Paré Not yet recruiting
    Boulogne, France, 92104
    Contact: Elisabeth Rouveix, MD
    Principal Investigator: Elisabeth Rouveix, MD
    Hôpital Antoine Béclère Not yet recruiting
    Clamart, France, 92141
    Contact: François Boué, MD
    Principal Investigator: François Boué, MD
    Hôpital Louis Mourier Not yet recruiting
    Colombes, France, 92700
    Contact: Emmanuel Mortier, MD
    Principal Investigator: Emmanuel Mortier, MD
    Hôpital Henry Mondor Not yet recruiting
    Creteil, France, 94010
    Contact: Sebastien Gallien, MD
    Principal Investigator: Sebastien Gallien, MD
    Hôpital Raymond Poincaré Not yet recruiting
    Garches, France, 92380
    Contact: Pierre de Truchis, MD
    Principal Investigator: Pierre de Truchis, MD
    Hôpital de Bicêtre Not yet recruiting
    Le Kremlin Bicêtre, France, 94275
    Contact: Antoine Cheret, MD
    Principal Investigator: Antoine Cheret, MD
    Centre Hospitalier Marc Jacquet Not yet recruiting
    Melun, France, 77011
    Contact: Nicolas Vignier, MD
    Principal Investigator: Nicolas Vignier, MD
    Hôpital Cochin Not yet recruiting
    Paris, France, 75006
    Contact: Nicolas Dupin, MD
    Principal Investigator: Nicolas Dupin, MD
    Hôpital Hôtel Dieu Not yet recruiting
    Paris, France, 75181
    Contact: Jean-Paul Viard, MD
    Principal Investigator: Jean-Paul Viard, MD
    Hôpital Saint-Louis Recruiting
    Paris, France, 75475
    Contact: Jean-Michel Molina, MD
    Principal Investigator: Jean-Michel Molina, MD
    Hôpital Saint-Antoine Not yet recruiting
    Paris, France, 75571
    Contact: Pierre-Marie Girard, MD
    Principal Investigator: Pierre-Marie Girard, MD
    Hôpital Pitié-Salpétrière Not yet recruiting
    Paris, France, 75641
    Contact: Christine Katlama, MD
    Principal Investigator: Christine Katlama, MD
    Hôpital Pitié-Salpétrière Not yet recruiting
    Paris, France, 75651
    Contact: Anne Simon, MD
    Principal Investigator: Anne Simon, MD
    Hôpital Necker-Enfants Malades Not yet recruiting
    Paris, France, 75743
    Contact: Claudine Duvivier, MD
    Principal Investigator: Claudine Duvivier, MD
    Hôpital Bichat-Claude-Bernard Not yet recruiting
    Paris, France, 75876
    Contact: Yazdan Yazdanpanah, MD
    Principal Investigator: Yazdan Yazdanpanah, PR
    Hôpital Européen Georges Pompidou Not yet recruiting
    Paris, France, 75908
    Contact: Juliette Pavie, MD
    Principal Investigator: Juliette Pavie, MD
    Hôpital Tenon Not yet recruiting
    Paris, France, 75970
    Contact: Gilles Pialoux, MD
    Principal Investigator: Gilles Pialoux, MD
    CHI Poissy Saint Germain en Laye Not yet recruiting
    Saint Germain en Laye, France, 78105
    Contact: Yves Welker, MD
    Principal Investigator: Yves Welker, MD
    Hôpital Foch Not yet recruiting
    Suresnes, France, 92151
    Contact: David Zucman, MD
    Principal Investigator: David Zucman, MD
    Hôpital André Mignot Not yet recruiting
    Versailles, France, 78157
    Contact: Alix Greder-Belan, MD
    Principal Investigator: Alix Greder-Belan, MD

    Sponsors and Collaborators

    French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

    Investigators

    Principal Investigator: Jean-Michel MOLINA, Pr Hôpital Saint Louis, Paris, FRANCE
    Study Chair: Jade GHOSN, MD Hôpital Hôtel-Dieu, Paris, FRANCE
    More Information

    More Information

    Additional Information:

    sponsor of the study

    Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)  
    ClinicalTrials.gov Identifier: NCT03113123   History of Changes  
    Other Study ID Numbers: ANRS PREVENIR  
      2016-A01577-44  
    Study First Received: April 10, 2017  
    Last Updated: May 12, 2017  
    Individual Participant Data    
    Plan to Share IPD: No  

    Studies a U.S. FDA-regulated Drug Product: No  
    Studies a U.S. FDA-regulated Device Product: No  

    Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

    Adherence
    Prevention
    Tenofovir
    Emtricitabine
    Antiretroviral
    Prophylaxis
    Men who have sex with men

    Additional relevant MeSH terms:
    HIV Infections
    Tenofovir
    Emtricitabine
    Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

    ClinicalTrials.gov processed this data on October 19, 2017
    This information is provided by ClinicalTrials.gov.